Eritoran tetrasodium (E5564) Treatment for Sepsis: Review of Preclinical and Clinical Studies

Documenti analoghi

• Risk of death and the efficacy of eritoran tetrasodium (E5564): Design considerations for clinical trials of anti-inflammatory agents in sepsis(*)
  di: Barochia, Amisha V., et al.
  Pubblicazione: (2010)
• Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies
  di: Altaweel, Laith, et al.
  Pubblicazione: (2009)
• The Surviving Sepsis Campaign's Revised Sepsis Bundles
  di: Barochia, Amisha V., et al.
  Pubblicazione: (2013)
• The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death
  di: Qiu, Ping, et al.
  Pubblicazione: (2011)
• Inhibition of Corneal Inflammation by the TLR4 Antagonist Eritoran Tetrasodium (E5564)
  di: Sun, Yan, et al.
  Pubblicazione: (2008)